EDAP TMS ADR Logo
US2683111072
908548
EDAP

EDAP TMS ADR

Forecast

The analysts' average price target is €9.11 (+282.77%). The median is €9.11 (+282.77%).

Buy
  5
Hold
  3
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • EDAP TMS closes overallotment option and expects 5.6 million USD in proceeds

    EDAP TMS reports that the syndicate banks fully exercised the 30‑day overallotment option and an additional 1,263,750 ADS will be issued. The action follows the initial placement of 8,425,000 ADS at 4.75 USD each; the issuance of the additional ADS is planned for Wednesday. The company expects net proceeds from this portion of the placement of around 5.6 million USD before estimated offering expenses. » More on de.investing.com


  • EDAP TMS renames itself FocalTherics and changes ticker to FOCL

    EDAP TMS will trade under the new name FocalTherics and the Nasdaq ticker FOCL starting June 1, 2026, to emphasize its focus on robot-assisted focal therapy. The company plans to report its extracorporeal shock wave lithotripsy and distribution segments as discontinued operations from Q2 2026. The stock rose 135% over the past year; the American depositary shares will remain listed on Nasdaq and shareholders do not need to take any action due to the name and ticker change. FocalTherics will hold an investor day on June 1 to present its new identity, strategy and outlook. » More on de.investing.com


  • EDAP signs letter of intent with Telix to integrate PSMA‑PET into Focal One HIFU

    EDAP has signed a letter of intent with Telix to explore collaboration in clinical research and education that evaluates combining the robotic Focal One HIFU system with Telix's PSMA‑PET imaging for prostate cancer treatment. The plan is to investigate integrating PSMA‑PET scans into therapy planning and patient monitoring for initial treatment and salvage therapy after radiotherapy. The letter of intent carries no financial obligations and does not commit either party to a definitive agreement. » More on de.investing.com


  • EDAP TMS beats revenue forecasts in Q1 2026, stock surges pre-market

    EDAP TMS reported Q1 2026 revenue of $15.42 million, beating the $14.77 million forecast; the HIFU segment grew 78% and contributed to an overall revenue increase of 25% year-over-year. Earnings per share came in worse than expected at -$0.2077 (vs. -$0.19 expected) and the operating loss widened to $7.4 million. Despite profitability issues, the stock rose 14.88% pre-market as management seeks further expansion of the HIFU platform in the U.S. and internationally, but gave a cautious outlook with continued losses expected. » More on de.investing.com


  • EDAP TMS: record growth in HIFU business despite revenue decline

    EDAP TMS reported Q4 2025 HIFU revenue growth of 34% to €11.7m, while total revenue fell 7% to €18.9m due to strategic reductions in non‑core areas. The company recorded technological advances including FDA approval for the new Focal‑One system and is advancing expansion into new indications such as endometriosis and BPH. Gross margin was 42.6% (normalized 46.9%), and net loss was €8.2m versus €1.9m a year earlier. The stock rose 3.38% premarket; management emphasizes continued focus on HIFU growth but cites currency and tariff risks and competitive pressure as challenges. » More on de.investing.com

Financials

In the last quarter, EDAP TMS ADR had revenue of €8.68M and net profit of -€3.94M

(EUR) September 2026
YoY
Revenue 8.68M 46.50%
Gross profit 4.46M 36.07%
Net profit -3.94M 32.77%
EBITDA -4.04M 28.96%

Fundamentals

Metric Value
Market capitalization
€162.43M
Number of shares
37.48M
52-week high/low
€4.60 - €1.10
Dividends No
Beta
-0.08
P/E ratio
-2.66
PEG ratio
0.05
P/B ratio
3.10
P/S ratio
1.56

Company profile

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.

Name
EDAP TMS ADR
CEO
Ryan Rhodes
Headquarters Vaulx-en-Velin,
France
Website
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO
08/01/1997
Employees 289

Ticker symbols

Exchange Symbol
NASDAQ
EDAP
Frankfurt
EDA.F
Düsseldorf
EDA.DU
München
EDA.MU
🍪

Parqet  uses cookies. Learn more